Clinical Trials Logo

Recurrent Ewing Sarcoma clinical trials

View clinical trials related to Recurrent Ewing Sarcoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05042934 Withdrawn - Clinical trials for Recurrent Ewing Sarcoma

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

Start date: September 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma.